ERBB2 and breast cancer: Others have also shown that pharmacologic modulation of glutamate signaling in ER negative, progesterone receptor negative, and human epidermal growth factor receptor 2 (HER2) negative breast cancer cells induces apoptosis, inhibits angiogenesis, and reduces tumor cell growth in vitro and in vivo [4–6].